Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Indiana University, Riley Hospital for Children, Indianapolis, IN.
J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e278-e281. doi: 10.1097/MPH.0000000000002147.
Peripheral T-cell lymphoma (PTCL) is an aggressive tumor, rarely seen in pediatrics or adolescent and young adults (AYAs) so there is no upfront or relapsed standard of care. The authors describe a 16-year-old with PTCL, treated with chemotherapy and autologous stem cell transplant. Upon relapse, he received ifosfamide, carboplatin, etoposide, and radiation with durable remission of 4 years. Data in pediatric/AYA PCTL continue to lack an understanding of the biology and microenvironment, the differences to adult patients, and a lack of adequate therapy. Targeted therapy may improve outcomes for children and AYAs with refractory or relapsed PTCL.
外周 T 细胞淋巴瘤 (PTCL) 是一种侵袭性肿瘤，在儿科或青少年和年轻成人 (AYA) 中很少见，因此没有标准的初始或复发治疗方法。作者描述了一名患有 PTCL 的 16 岁患者，接受了化疗和自体干细胞移植治疗。在复发时，他接受了异环磷酰胺、卡铂、依托泊苷和放疗，缓解持续了 4 年。儿科/AYA PCTL 的数据仍然缺乏对生物学和微环境的了解，与成人患者的差异，以及缺乏足够的治疗方法。靶向治疗可能改善耐药或复发的 PTCL 儿童和 AYA 的预后。
